Please login to the form below

Not currently logged in
Email:
Password:

Dr Maurice Chagnaud appointed as new CEO of Polpharma

Will take the reins at the Polish pharmaceutical group week
Polpharma Maurice Chagnaud

Polish pharmaceutical group Polpharma has appointed Dr Maurice Chagnaud as its new CEO.

He will join the company next week from Lupin where he was a group president with an inhalation remit for Europe, Russia & CIS.

Prior to that Dr Chagnaud held senior roles at Teva, Mylan and Merck Generics during a career that has so far seen him amass more than 20 years of European pharma management experience.

Polpharma operates across Europe, CIS and Central Asia and has manufacturing subsidiaries in Poland, Russia and Kazakhstan. It's the largest Polish pharmaceutical group and wants Dr Chagnaud to help it become a regional leader in CEE, CIS and Central Asia.

Jerzy Starak, chairman of Polpharma's supervisory board, said: “Polpharma's strategic goal is to become a regional leader and grow outside of our current boundaries. We are impressed by the extensive experience of Mr Chagnaud, gained in international companies such as Merck Generics, Teva and Lupin, where his achievements included building regional strategies and transforming organisations to meet new challenges.

“I am confident that he will manage Polpharma effectively, identify and pursue new opportunities, and motivate our team to deliver outstanding performance to secure the long-term growth of our group.”

As Polpharma CEO Dr Chagnaud will succeed Markus Sieger, who has been delegated by the Supervisory Board to exercise supervision over the company for the last six months, and who will remain a member of the Supervisory Board.

30th September 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...
Why empathy in digital patient recruitment is vital
This is where empathy mapping can be incredibly effective....